Bristol-Myers Shares, With Few `Buys,' May Rise More on Experimental Drugs

(Bloomberg) -- Just when a majority of analysts say
Bristol-Myers Squibb Co. has done about all it can for
shareholders, new medicines for diabetes and cancer, together
with takeover speculation, may keep the stock rising.

Seventeen of 23 analysts surveyed by Bloomberg rate the
stock ``hold'' or ``sell'' after the New York-based drugmaker
reached the highest in five years. Bristol-Myers's revived
research pipeline helped the shares to the second-biggest gain
among the eight largest U.S. drugmakers this year.


Read more at Bloomberg Stocks News

Bristol pleads guilty in Plavix case

(Reuters) - Bristol-Myers on May 30 said it had agreed to pay the fine to resolve charges that it illegally concealed a patent settlement deal it had reached with Apotex Inc., a generic drugmaker based in Canada.




But privately held Apotex subsequently launched its cheaper copycat form of the drug to prevent blood clots, after the arrangement between it and Bristol-Myers collapsed due to opposition from state attorneys general in the United States.


Read more at Reuters.com Business News